Casdin Capital as of Dec. 31, 2017
Portfolio Holdings for Casdin Capital
Casdin Capital holds 26 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sage Therapeutics (SAGE) | 10.0 | $41M | 250k | 164.71 | |
| Foundation Medicine | 8.6 | $36M | 520k | 68.20 | |
| Loxo Oncology | 7.4 | $30M | 360k | 84.18 | |
| Blueprint Medicines (BPMC) | 6.4 | $26M | 348k | 75.41 | |
| Bluebird Bio | 6.3 | $26M | 145k | 178.10 | |
| Alnylam Pharmaceuticals (ALNY) | 6.2 | $25M | 200k | 127.05 | |
| Myokardia | 5.7 | $24M | 560k | 42.10 | |
| Sangamo Biosciences (SGMO) | 5.6 | $23M | 1.4M | 16.40 | |
| Global Blood Therapeutics In | 4.9 | $20M | 515k | 39.35 | |
| Voyager Therapeutics (VYGR) | 4.6 | $19M | 1.1M | 16.60 | |
| Agios Pharmaceuticals (AGIO) | 4.5 | $18M | 320k | 57.16 | |
| Fate Therapeutics (FATE) | 3.9 | $16M | 2.6M | 6.11 | |
| Spark Therapeutics | 3.8 | $16M | 303k | 51.42 | |
| Codexis (CDXS) | 3.2 | $13M | 1.6M | 8.35 | |
| Evolent Health (EVH) | 3.2 | $13M | 1.1M | 12.30 | |
| Audentes Therapeutics | 3.0 | $13M | 400k | 31.25 | |
| GenMark Diagnostics | 2.8 | $11M | 2.7M | 4.17 | |
| Illumina (ILMN) | 2.3 | $9.6M | 44k | 218.50 | |
| Clovis Oncology | 2.1 | $8.7M | 128k | 68.00 | |
| Jounce Therapeutics | 1.5 | $6.1M | 475k | 12.75 | |
| Editas Medicine (EDIT) | 1.0 | $4.1M | 133k | 30.73 | |
| Cytomx Therapeutics (CTMX) | 0.9 | $3.7M | 178k | 21.11 | |
| Syros Pharmaceuticals | 0.7 | $2.7M | 274k | 9.73 | |
| Gilead Sciences (GILD) | 0.5 | $2.1M | 30k | 71.63 | |
| Beigene (ONC) | 0.4 | $1.8M | 18k | 97.72 | |
| Ovid Therapeutics (OVID) | 0.4 | $1.6M | 160k | 9.87 |
